Interestingly, as focusing on the interaction subgroup of patients who were both younger than 70 years old and at cancer stage I or II, there was a significantly higher risk of VTEs (HR: 8.73, 95% CI: 1.90–40.23, p = 0.0054) in GnRH users compared with non-users. This evidence concerns the gene GNRH1 and cancer.